Login
$SABS
$3.00 +$0.04 (1.35%) Live

$SABS SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
22 Oct 2026 25-NSE
13 Oct 2026 8-K: Other Events

Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes

18 Sep 2026 Form 4: Kropotova Alexandra, CHIEF MEDICAL OFFICER

Gave up 473 shares to cover exercise price or tax

21 Aug 2026 424B3
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 SCHEDULE 13G
10 Aug 2026 SCHEDULE 13D/A
06 Aug 2026 10-Q
07 Jul 2026 8-K: Regulation FD Disclosure

MIAMI, July 7, 2026 – Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-th...

26 Jun 2026 Form 4: Kropotova Alexandra, CHIEF MEDICAL OFFICER

Gave up 988 shares to cover exercise price or tax

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 77,966,409, ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support